[Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis]

Y N Zhao; J Y Fu; J He; D S Fan

doi:10.3760/cma.j.cn112138-20220708-00498

[Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis]

Zhonghua Nei Ke Za Zhi. 2023 Jul 1;62(7):885-890. doi: 10.3760/cma.j.cn112138-20220708-00498.

[Article in Chinese]

Authors

Y N Zhao¹, J Y Fu², J He², D S Fan²

Affiliations

¹ Peking University Third Hospital, Beijing 100191, China.
² Department of Neurology, Peking University Third Hospital, Beijing Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking University, Beijing 100191, China.

PMID: 37394863
DOI: 10.3760/cma.j.cn112138-20220708-00498

Abstract

尿酸是人体内嘌呤代谢的终产物，主要通过影响能量代谢、氧化应激、炎症反应等通路来影响肌萎缩侧索硬化症（ALS）的发生发展，但目前尿酸对于ALS的作用仍然存在争议。动物实验显示降尿酸药物黄嘌呤氧化酶抑制剂可以延缓动物模型发病、延长生存期、减缓体重下降、延缓运动能力下降，提示降尿酸药物，尤其是黄嘌呤酶抑制剂在ALS中应用的潜在可能性。.

MeSH terms

Amyotrophic Lateral Sclerosis* / drug therapy
Humans
Uric Acid

Substances

Uric Acid